-
Corticosteroid treatment is associated with
a reduced risk of mortality for people taking tuberculosis (TB) therapy,
results of a meta-analysis published in The Lancet
Infectious Diseases show. Treatment with steroids was associated with a
significant 17% reduction in mortality risk, ...
24 March 2013 | Michael Carter
-
Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at
much higher doses than used in current clinical practice – suggesting that much
higher drug levels may lead to a more rapid treatment response, allowing the
treatment ...
07 March 2013 | Keith Alcorn
-
A new two-drug combination of rifapentine and moxifloxacin
can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month
continuation phase, Dr Amina Jindani of St George’s University Medical School,
London, told the 20th Conference on Retroviruses and ...
07 March 2013 | Keith Alcorn
-
Bedaquiline, the first agent in a new class
of TB drug, has been recommended for accelerated approval by the Anti-Infective
Drugs Advisory Committee of the United States Food and Drug Administration
(FDA).
The committee voted unanimously (18 to 0) ...
03 December 2012 | Lesley Odendal
-
People living with HIV who have a history of
active tuberculosis (TB) have a significant risk of the recurrence of the
disease, investigators report in the online edition of Clinical Infectious Diseases.
The risk of developing active TB ...
22 October 2012 | Michael Carter
-
Results of an international study published
in The Lancet show that 7% of
people receiving second-line treatment for tuberculosis (TB) have extensively
drug-resistant TB (XDR-TB). The investigators describe this finding as “worrying”.
A total of 1278 people from eight
countries were ...
31 August 2012 | Michael Carter
-
Raltegravir seems to be a suitable alternative
to efavirenz for HIV-TB co-infected patients while receiving TB treatment,
according to 24-week results of the ANRS 12 180 REFLATE study presented at the
Nineteenth International AIDS Conference (AIDS 2012) in Washington ...
31 July 2012 | Lesley Odendal
-
A
new TB drug, PA-824, showed very potent early bactericidal activity in a
randomised 14-day study in people with TB, when used in combination with the established
antibiotic moxifloxacin, and pyrazinamide, an existing TB drug, according to a
presentation by ...
25 July 2012 | Theo Smart
-
Standard dosing of efavirenz, that was not
adjusted for patient weight, resulted in therapeutic efavirenz concentrations
and excellent virological outcomes in patients coinfected with TB and HIV who
were also taking a rifampicin-containing TB treatment, according to results
from the ...
24 July 2012 | Lesley Odendal
-
People with HIV reduce their overall risk
of tuberculosis (TB) by starting antiretroviral therapy, an international team
of investigators report in the online edition of Clinical Infectious Diseases. Despite this, the risk of the disease
increased in the first ...
11 April 2012 | Michael Carter
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Impact of switching to generic drugs in the UK – survey results 11 June 2013A recent NAM survey shows that people living with HIV...
HIV cure research – free webinar 28 May 2013As part of its European HIV prevention work, NAM is
collaborating...
New resources to support shared decision making in HIV care 21 May 2013There’s been lots of interest
recently in the concept of shared...